Compare CCEL & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEL | HBIO |
|---|---|---|
| Founded | 1989 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 24.9M |
| IPO Year | 2022 | 2000 |
| Metric | CCEL | HBIO |
|---|---|---|
| Price | $3.50 | $6.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 6.3K | ★ 26.1K |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $25,384,279.00 | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | $350.00 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $2.72 | $0.38 |
| 52 Week High | $5.52 | $7.50 |
| Indicator | CCEL | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 53.07 |
| Support Level | $3.18 | $6.05 |
| Resistance Level | $3.57 | $7.00 |
| Average True Range (ATR) | 0.21 | 0.44 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 65.43 | 67.58 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.